GE Healthcare

As a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. GE Healthcare’s Vizamyl™ (Flutemetamol F18 injection) is a radioactive diagnostic agent approved by the FDA for use in PET imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease or other causes of cognitive decline. Visit for more information.